Methods and materials for characterizing and modulating interaction between heregulin and HER3
View Patent ↗The disclosure provided herein identifies and characterizes the domain in HER3 receptor that interacts with heregulin ligand. Typical embodiments of the invention disclosed herein include methods for identifying compounds which specifically bind the heregulin binding domain in HER3.
1. A method of identifying a compound which specifically binds the heregulin binding domain in a HER3 variant polypeptide consisting of amino acid 20 to amino acid 329 of HER3 polypeptide sequence of SEQ ID NO: 2 comprising contacting the HER3 variant polypeptide with a test compound and determining whether the test compound specifically binds to the HER3 variant.
2. The method of claim 1 , further comprising determining whether the test compound is an inhibitor of the heregulin induced tyrosine phosphorylation of HER3(SEQ ID NO: 2), comprising the steps of:
contacting mammalian cells that express HER3 receptor with heregulin in the presence and absence of the test compound; and
monitoring the mammalian cells for an inhibition of tyrosine phosphorylation of HER3 (SEQ ID NO: 2) in the presence of the test compound as compared to the absence of the test compound.
3. The method of claim 1 , further comprising determining whether the test compound is an enhancer of the heregulin induced tyrosine phosphorylation of HER3 (SEQ ID NO: 2), comprising the steps of:
contacting mammalian cells that express HER3 receptor with heregulin in the presence and absence of the test compound; and
monitoring the mammalian cells for an increase of tyrosine phosphorylation of HER3 (SEQ ID NO: 2) in the presence of the test compound as compared to the absence of the test compound.
4. A method of determining whether a test compound modulates the interaction between heregulin polypeptide of SEQ ID NO: 4 and a HER3 variant polypeptide consisting of amino add 20 to amino acid 329 of HER3 polypepride sequence of SEQ ID NO:2 comprising the steps of:
(a) contacting the HER3 variant polypeptide with a test compound;
(b) contacting the HER3 variant polypeptide of step (a) with heregulin;
(c) comparing the binding interaction between the HER3 variant polypeptide and heregulin of step (b) wit the binding interaction between HER3 variant polypeptide and heregulin in the absence of the test compound.